Kogenate ® FS : antihemophilic factor rFVIII-FS

  title={Kogenate ® FS : antihemophilic factor rFVIII-FS},
  author={J. Lusher and Meera B Chitlur},
10.1586/14750708.3.6.699 © 2 Characterization of the factor VIII (FVIII) gene and expression of factor VIII through recombinant technology paved the way for the availability of recombinant factor VIII (rFVIII) for intravenous infusion, a significant breakthrough in the treatment of hemophilia A. Kogenate® FS (rFVIII-FS) is a native, full-length factor VIII molecule, produced from a baby hamster kidney cell line, purified and formulated without the addition of albumin, and stabilized with… CONTINUE READING


Publications citing this paper.

Sucrose-Formulated Octocog Alfa

View 9 Excerpts
Highly Influenced


Publications referenced by this paper.
Showing 1-10 of 56 references

Evaluation of user preference for a needleless factor VIII delivery device for haemophilia patients

R Butler, P Larson, S Mannix
J. Outcomes Res • 2004
View 6 Excerpts
Highly Influenced

Initial results of a randomized, prospective trial of prophylaxis to prevent joint disease in young children with factor VIII (FVIII) deficiency

M Manco-Johnson, T Abshire, D Brown
Blood (ASH Annual Meeting Abstracts) • 2005
View 1 Excerpt

A population

EL Saenko, SW Pipe

A survey of factor prophylaxis in the Canadian haemophilia A population.

Haemophilia : the official journal of the World Federation of Hemophilia • 2004

Continuous infusion of Kogenate FS for hemostasis for surgery in hemophilia

A Viswabandya, V Lee, V Cherian
Haemophilia 10(S3), • 2004

Patients ' satisfaction with a new reconstitution system for Kogenate Bayer : initial German experiences

G Goldmann, R Klamroth, V Haupt, E Kellermann
J . Outcomes Res . • 2004

final report on a hallmark clinical investigation

J Lusher, C Abildgaard, A Arkin S et al. Human recombinant DNA-derived antih hemophilia
J. Thromb. Haemost. 2, 574–583 • 2004

Similar Papers

Loading similar papers…